United Kingdom-based AstraZeneca's oncology immunotherapy Imfinzi (durvalumab) has received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of small cell lung cancer (SCLC), it was reported yesterday.
Last month, a phase three trial called CASPIAN met its primary endpoint with Imfinzi by delivering a statistically-significant and clinically-meaningful improvement in overall survival for patients suffering from extensive-stage SCLC.
The CASPIAN trial assessed Imfinzi in combination with standard-of-care etoposide and platinum-based chemotherapy against chemotherapy alone. The drug is also being assessed in limited-stage SCLC after concurrent chemoradiation therapy in a phase three trial, called ADRIATIC. Imfinzi is a human monoclonal antibody, which has been designed to target the PD-1/PD-L1 pathway.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid